Skip to content

Connectivity Alterations After Levetiracetam Application

Connectivity Alterations of Brain Network in LGG Patients After Levetiracetam Application at Short Term

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04425798
Enrollment
30
Registered
2020-06-11
Start date
2022-05-25
Completion date
2022-09-30
Last updated
2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Glioma

Keywords

glioma, glioma-related epilepsy, levetiracetam, connectivity alteration

Brief summary

This study aimed to analyze the connectivity alterations in brain networks of LGG patients with epilepsy who take levetiracetam at short-term preoperatively.

Detailed description

Glioma-related epilepsy (GRE) is a very common symptom in patients with diffuse gliomas. Approximately 60% of patients with low-grade gliomas (LGGs) and 40-64% of patients with high-grade gliomas presented with GRE at the onset. Although beneficial for the control of GRE, the overall therapeutic effect was unsatisfied and over 20% of patients still suffered from seizures. GRE was found to be associated with brain network and functional connectivity. And it has been reported that temporal lobe seizures could induce functional connectivity and decreased network efficiency of brain networks. However, the alterations in functional networks induced by GRE were still unclear. And LGG patients with GRE usually take levetiracetam (LEV) preoperatively, which could effectively reduce abnormal spike activity and further cause connectivity alterations. This makes it more complex to reveal the connectivity alterations of brain networks in LGG patients with GRE. This study aimed to collect the resting-state functional MRIs of 30 LGG patients who presented with GRE at the onset. Through further applied graph theory analysis, investigators tend to reveal the connectivity alterations of brain networks caused by levetiracetam. The findings of this study will provide a theoretical basis for further study of connectivity alterations of brain networks in patients with GRE.

Interventions

None listed

Sponsors

Beijing Tiantan Hospital
CollaboratorOTHER
Beijing Neurosurgical Institute
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years; * Histopathological diagnosis with LGG according to the 2016 World Health Organization (WHO) criteria; * Participants received more than 6 years of school education; * Presence of GRE, take levetiracetam less than 1 month; or do not take any medicine and receive any treatment; * No history of biopsy, radiotherapy, or chemotherapy.

Exclusion criteria

* Contraindications for MRI; * Head motion greater than 3 mm in translation or 3° in rotation;

Design outcomes

Primary

MeasureTime frameDescription
The connectivity alterations of brain networks in patients with and without levetiracetam applicationthrough study completion, an average of 2 yearsGraph theory analysis is used to delineate topological networks with resting-state functional MRIs and investigated the characteristics of functional networks. Global and nodal topological properties of brain networks are calculated in the two groups of patients. The difference of topological properties of brain networks between patients with and without levetiracetam application are analyzed using t-test or chi-square test according to the type of data.

Countries

China

Contacts

Primary ContactTao Jiang, MD and PhD
taojiang1964@163.com+86-010-67021832
Backup ContactLianwang Li, MD
ttyyllw@163.com+86 18810647541

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026